Search from website

SARS-CoV-2 Spike S1 B.1.621 (mu)

 

Figure 1. Coomassie-stained SDS-PAGE analysis of SARS-CoV-2 Spike S1 B.1.621. 4-12% gradient gel is used for analysis. Lane 1. 8 µg SARS-CoV-2 Spike S1 B.1.621 (-DTT). Lane 2. Protein marker (Smobio). Lane 3. 8 µg SARS-CoV-2 Spike S1 B.1.621 (+DTT).

       

Figure 2. HPLC analytical SEC for final product.

       

Figure 3. HPLC analytical SEC after 3 freeze-thaw cycles.

       

Figure 4. Octet RED96e analysis of SARS-CoV-2 Spike S1 B.1.621 binding to the ACE2 receptor.

Select volume:

Quantity:

€ 1500

Catalogue #

P-362-100

Name

SARS-CoV-2 Spike S1 B.1.621 (mu)

Description

Protein contains amino acids 14-681, mutations T95I, Y144S, Y155N, R346K, E484K, N501Y, D614G, P681H two extra amino acids (AS) in N-terminus and His-6 tag at C-terminus and GSG linker between protein and tag.

Uniprot ID

P0DTC2

MW

75.78 kDa

Host

CHO-based cell line (expressed by QMCF Technology)

Purification

Purified by Ni-affinity chromatography and gel-filtration from serum-free CHO growth media, sterile filtrated

Purity

>95%

Concentration

1 mg/ml

Buffer

PBS pH 7.4

Endotoxine

NA

QC

SDS-PAGE, NanoDrop A280, Analytical SEC, Octet binding to ACE2

Shipping

Shipped on dry ice.

Storage

Store at -70°C upon receipt. Recommended to aliquot into smaller quantities. Avoid repeated freeze-thaw cycles

This product is for research use only

TECHNICAL ASSISTANCE

Please refer any technical questions to

technical.support@icosagen.com

Our locations

United States Office

77 Geary St. 5th Floor
San Francisco, CA 94108
+1 415 548 6625

European Office

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070
error:
Shopping Cart